Sun, Dec 21, 2014, 4:42 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • botechgod botechgod Jul 17, 2004 11:10 AM Flag

    MD's will kill BSX

    as a surgeon, the worst moment you can ever have is telling a family that their loved one is dead or severely injured following a medical procedure-sleepless nights, lawsuits are sure to follow. There are plenty of stents, no cardiologist is going to risk his/her career on this crappy (bsx) stent. Even if the late restenosis for bsx is lower, the threat of immediate complications and facing a pissed off and grieving family will deter any physician from using this product. Furthermore, patients (at least insured ones) come to doctors offices with all kinds of info from the internet (at least for elective procedures). You can be sure they are going to demand anything but a bsx stent. Longs better hope this stent debacle doesnt spill over to other bsx produsts. Also, not to piss longs off, but seriously why did you hold on to this stock when it was trading close to 52 wk high and news has been out for a while that there were serious problems with the stent? NEVER TRUST MANAGEMENT OF ANY COMPANY< REMEMBER THEY ARE NOT PRIESTS, JUST PEOPLE WHOSE HIGHEST PRIORITY IN LIFE IS MAKING MONEY>

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • As a surgeon?

      You're no surgeon!

      If you were one, you would fully understand the issue and feel great that the new improved models are coming overnight!

      The BSX stent is the best thing to ever happen for cardiology and patient care, in the last 50 years!

      Take THAT from a real cardiovascular practitioner!

      Go back to medical school!

    • Remember Tylenol.... When a company does the right thing the markets rewards it.

      As a JNJ shareholder I'm very concerned that each day that Cordis ships product, certified as "adulterated" by FDA, that a major recall could be more damaging to share price.

      It's interesting to note the differce in approach to handling QSR/GMP issues between BSC and JNJ. While JNJ has become adversarial to FDA's finding (April, 04) that Cypher is "adulterated" (defined in the CFR as "not fit for use"), BSC on the other hand has embraced the QSR/GMP's and quickly informed FDA that it had a problem. FDA has acknowledged BSC cooperation and used its discretion to expand the definition of affected lots. Tellingly, you don't see BSC stonewalling FDA on their expanded definition, like Cordis is doing with Cypher.

      Contrary to your byline, physicians will be the ones who will lead the way in rewarding BSC for quickly admitting error and fixing the problem.

    • MD's will kill BSX
      by: botechgod (35/M/north brunswick, NJ) 07/17/04 11:10 am
      Msg: 29609 of 29621

      >>as a surgeon, the worst moment you can ever have is telling a family that their loved one is dead or severely injured following a medical procedure-sleepless nights, lawsuits are sure to follow. There are plenty of stents, no cardiologist is going to risk his/her career on this crappy (bsx) stent.>>

      Surgeon my ass, botech....dissecting earthworms in your mom's backyard hardly qualifies. Nice technical jargon in your post: "crappy stent"...wow, good choice of words, dumb ass.
      The Core

    • You must be a JNJ sales rep. If your sales approach is to use scare tactics with Doctors about Taxus they are going to laugh you right out of the office.

      The BSX rep will have already been there explaining that the fix has been in for some time and that for safety reasons all prefix stents have been removed from the supply chain. Clear and simple.

      The Docs loved Taxus before the recall and with improved safety they will love it still.

      This to shall pass.

 
BSX
13.15-0.11(-0.83%)Dec 19 4:03 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.